DRUG vs. TNXP

Last updated Jun 24, 2026

DRUG (Bright Minds Biosciences Inc) and TNXP (Tonix Pharmaceuticals Holding Corp.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, DRUG returned 22.77%/yr vs -88.88%/yr for TNXP. At a 0.06 correlation, their price movements are largely independent.

Performance

DRUG vs. TNXP - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Bright Minds Biosciences Inc (DRUG) and Tonix Pharmaceuticals Holding Corp. (TNXP). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, DRUG achieves a -16.54% return, which is significantly higher than TNXP's -23.43% return.

DRUG

• 1D: 2.58%
• 1M: -22.00%
• YTD: -16.54%
• 6M: -22.71%
• 1Y: 140.42%
• 3Y*: 180.55%
• 5Y*: 22.77%
• 10Y*: —

TNXP

• 1D: -1.97%
• 1M: -6.34%
• YTD: -23.43%
• 6M: -28.72%
• 1Y: -63.53%
• 3Y*: -86.73%
• 5Y*: -88.88%
• 10Y*: -84.30%

*Multi-year figures are annualized to reflect compound growth (CAGR)

DRUG vs. TNXP - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021
DRUG Bright Minds Biosciences Inc	-16.54%	116.66%	2,418.88%	-61.35%	-76.66%	-39.45%
TNXP Tonix Pharmaceuticals Holding Corp.	-23.43%	-52.64%	-97.44%	-83.46%	-96.59%	-75.33%

Correlation

The correlation between DRUG and TNXP is 0.28, which is low. Their price movements are largely independent, making them effective diversification partners.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.28
Correlation (3Y) Calculated over the trailing 3-year period	0.06
Correlation (5Y) Calculated over the trailing 5-year period	0.06
Correlation (All Time) Calculated using the full available price history since Mar 22, 2021	0.06

Over the past year, DRUG and TNXP have become more correlated (0.28) than their long-term average of 0.06, meaning their price movements have been converging.

Fundamentals

Market Cap DRUG : $624.59M TNXP : $163.94M
EPS DRUG : -CA$3.48 TNXP : -$11.15
PB Ratio DRUG : 2.88 TNXP : 0.72
Total Revenue (TTM) DRUG : CA$0.00 TNXP : $17.56M
Gross Profit (TTM) DRUG : -CA$20.13K TNXP : $10.28M
EBITDA (TTM) DRUG : -CA$31.36M TNXP : -$149.18M

Return for Risk

DRUG vs. TNXP — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

DRUG

DRUG Risk / Return Rank: 86
DRUG Sharpe Ratio Rank: 88
DRUG Sortino Ratio Rank: 86
DRUG Omega Ratio Rank: 81
DRUG Calmar Ratio Rank: 87
DRUG Martin Ratio Rank: 87

TNXP

TNXP Risk / Return Rank: 14
TNXP Sharpe Ratio Rank: 11
TNXP Sortino Ratio Rank: 11
TNXP Omega Ratio Rank: 13
TNXP Calmar Ratio Rank: 13
TNXP Martin Ratio Rank: 22

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

DRUG vs. TNXP - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Bright Minds Biosciences Inc (DRUG) and Tonix Pharmaceuticals Holding Corp. (TNXP). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.

	DRUG	TNXP	Difference
Sharpe ratio: Return per unit of total volatility	1.93	-0.73	+2.66
Sortino ratio: Return per unit of downside risk	2.67	-1.11	+3.78
Omega ratio: Gain probability vs. loss probability	1.30	0.88	+0.42
Calmar ratio: Return relative to maximum drawdown	3.68	-0.77	+4.45
Martin ratio: Return relative to average drawdown	9.54	-0.96	+10.50

DRUG vs. TNXP - Sharpe Ratio Comparison

The current DRUG Sharpe Ratio is 1.93, which is higher than the TNXP Sharpe Ratio of -0.73. The chart below compares the historical Sharpe Ratios of DRUG and TNXP, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Drawdowns

DRUG vs. TNXP - Drawdown Comparison

The maximum DRUG drawdown since its inception was -97.68%, roughly equal to the maximum TNXP drawdown of -100.00%. Use the drawdown chart below to compare losses from any high point for DRUG and TNXP.

Drawdown Indicators

	DRUG	TNXP	Difference
Max Drawdown Largest peak-to-trough decline	-97.68%	-100.00%	+2.32%
Max Drawdown (1Y) Largest decline over 1 year	-38.35%	-82.70%	+44.35%
Max Drawdown (3Y) Largest decline over 3 years	-76.98%	-99.87%	+22.89%
Max Drawdown (5Y) Largest decline over 5 years	-97.68%	-100.00%	+2.32%
Max Drawdown (10Y) Largest decline over 10 years	—	-100.00%	—
Current Drawdown Current decline from peak	-32.15%	-100.00%	+67.85%
Average Drawdown Average peak-to-trough decline	-58.73%	-91.17%	+32.44%
Ulcer Index Depth and duration of drawdowns from previous peaks	14.78%	66.20%	-51.42%

Volatility

DRUG vs. TNXP - Volatility Comparison

Bright Minds Biosciences Inc (DRUG) and Tonix Pharmaceuticals Holding Corp. (TNXP) have volatilities of 18.91% and 19.34%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	DRUG	TNXP	Difference
Volatility (1M) Calculated over the trailing 1-month period	18.91%	19.34%	-0.43%
Volatility (6M) Calculated over the trailing 6-month period	43.32%	51.35%	-8.03%
Volatility (1Y) Calculated over the trailing 1-year period	73.38%	86.85%	-13.47%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	662.99%	136.06%	+526.93%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	646.38%	140.79%	+505.59%

Dividends

DRUG vs. TNXP - Dividend Comparison

Neither DRUG nor TNXP has paid dividends to shareholders.

Tickers have no history of dividend payments

Financials

Frequently Asked Questions

Can I hold both DRUG and TNXP in my portfolio?

DRUG and TNXP have a correlation of 0.28, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, DRUG or TNXP?

TNXP has higher volatility (19.34%) compared to DRUG (18.91%). In terms of maximum drawdown, DRUG dropped -97.68% vs TNXP's -100.00%.

Which has better risk-adjusted returns?

DRUG currently has the higher Sharpe Ratio (1.93 vs -0.73), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.